Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges
Miguel García-Pardo, Maisam Makarem, Janice J.N. Li, Deirdre Kelly, Natasha B. Leighl
Abstract
In the current era of precision medicine, the identification of genomic alterations has revolutionised the management of patients with solid tumours. Recent advances in the detection and characterisation of circulating tumour DNA (ctDNA) have enabled the integration of liquid biopsy into clinical practice for molecular profiling. ctDNA has also emerged as a promising biomarker for prognostication, monitoring disease response, detection of minimal residual disease and early diagnosis. In this Review, we discuss current and future clinical applications of ctDNA primarily in non-small cell lung cancer in addition to other solid tumours.
Topics & Concepts
Liquid biopsyMinimal residual diseaseCell-free fetal DNACirculating tumor DNAMedicinePrecision medicineClinical PracticeBiomarkerDiseaseLung cancerMolecular diagnosticsPathologyOncologyComputational biologyBioinformaticsInternal medicineCancerBiologyGeneticsPregnancyFetusFamily medicineBone marrowPrenatal diagnosisCancer Genomics and DiagnosticsLung Cancer Treatments and MutationsRenal cell carcinoma treatment